Prof. Polina Stepensky, head of the department at Hadassah-University Medical Center in Jerusalem, Israel, has announced a groundbreaking treatment for multiple myeloma cancer. The treatment has a 90% success rate.
Must Watch: Would you live on 3D Printed Mars for a year for $60,000?
Hadassah-University Medical Center in Jerusalem’s Ein Kerem has announced an “unprecedented achievement” in the treatment of multiple myeloma cancer – the second-most common hematological disease. It accounts for one-tenth of all blood cancers and 1% of all types of malignancies.
The innovative treatment against the disease, which has long been considered incurable, was developed after a series of experiments carried out in the hospital’s bone-marrow transplant and immunotherapy department in recent years.
“We have a waiting list of over 200 patients from Israel and various parts of the world at any given time.”Polina Stepensky
“Now, in light of the impressive results of CAR-T treatments, it seems that they have many more years to live – and with an excellent quality of life,” said Prof. Polina Stepensky, head of the department.
The treatment is based on genetic engineering technology, which is an effective and groundbreaking solution for patients whose life expectancy was only two years until a few years ago. They have used a genetic engineering technology called CAR-T, or Chimeric Antigen Receptor T-Cell Therapy, which boosts the patient’s own immune system to destroy the cancer. More than 90% of the 74 patients treated at Hadassah went into complete remission, the oncologists said.
Subscribe to GreatGameIndia
“We have a waiting list of more than 200 patients from Israel and various parts of the world at any given time,” Stepensky said. “Due to the complexity of the production and the complexity of the treatment itself, only one patient a week enters the treatment, which is still being conducted as an experiment.”
Swedish researchers reported in a study published in the British Medical Journal that mRNA COVID-19 vaccines are linked to an increased risk of vaginal bleeding.